 DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA and Novo Nordisk AS Nasdaq Copenhagen: NOVO B today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothenas clinical stage antibody PRX004 and broader ATTR amyloidosis programme. 